Recent Transactions

Advised Supplier Participações, the largest credit fintech company in Brazil and the first independent mover in supply chain financing, on the sale of a majority stake to Totvs, the leading provider of management software and related consulting services in Brazil

Advised TT International, a leading independent asset management firm focused on managing high alpha, high conviction active management strategies for institutional investors, on its sale to Sumitomo Mitsui Financial Group, Inc.

Advising IFC and Principia Capital Partners on the sale of their stakes in Pravaler, Brazil’s leading provider of student loans for college students, to Itaú Unibanco, Brazil’s largest financial institution

Advised Westpac, the third largest company in Australia by market capitalization, on its exit of BT Advice and the sale of select assets to Viridian Advisory

Advised Hitachi, a leading global industrial conglomerate, on the sale of its LiB business including Hitachi Vehicle Energy

Advised ASX-listed AUB Group, a leading insurance intermediary business operating a network of over 100 insurance brokers and underwriting agencies across Australia and New Zealand, on its fully underwritten entitlement offer to raise A$116mm

Advised Blue Sky, an ASX-listed diversified alternative assets manager, on its response to an activist short-seller campaign, strategic review of recapitalisation options, and receipt of a A$50mm long-term capital investment by Oaktree via a 7-year senior secured convertible loan note facility

Advised TAL, Australia’s largest and leading insurance business that is 100% owned by Dai-ichi Life of Japan, on the acquisition of Suncorp Group Limited’s Australian Life Insurance business

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m) 

Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.